These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10439799)

  • 1. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas.
    François C; van Velthoven R; De Lathouwer O; Moreno C; Peltier A; Kaltner H; Salmon I; Gabius HJ; Danguy A; Decaestecker C; Kiss R
    Am J Clin Pathol; 1999 Aug; 112(2):194-203. PubMed ID: 10439799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers.
    Choufani G; Nagy N; Saussez S; Marchant H; Bisschop P; Burchert M; Danguy A; Louryan S; Salmon I; Gabius HJ; Kiss R; Hassid S
    Cancer; 1999 Dec; 86(11):2353-63. PubMed ID: 10590378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity.
    André S; Kojima S; Yamazaki N; Fink C; Kaltner H; Kayser K; Gabius HJ
    J Cancer Res Clin Oncol; 1999; 125(8-9):461-74. PubMed ID: 10480338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors.
    Schwarz G; Remmelink M; Decaestecker C; Gielen I; Budel V; Burchert M; Darro F; Danguy A; Gabius HJ; Salmon I; Kiss R
    Am J Clin Pathol; 1999 May; 111(5):623-31. PubMed ID: 10230352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker.
    Dancer JY; Truong LD; Zhai Q; Shen SS
    Arch Pathol Lab Med; 2010 Jan; 134(1):90-4. PubMed ID: 20073610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration.
    Camby I; Belot N; Rorive S; Lefranc F; Maurage CA; Lahm H; Kaltner H; Hadari Y; Ruchoux MM; Brotchi J; Zick Y; Salmon I; Gabius HJ; Kiss R
    Brain Pathol; 2001 Jan; 11(1):12-26. PubMed ID: 11145198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate.
    Ohannesian DW; Lotan D; Lotan R
    Cancer Res; 1994 Nov; 54(22):5992-6000. PubMed ID: 7954433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells.
    Glinsky VV; Huflejt ME; Glinsky GV; Deutscher SL; Quinn TP
    Cancer Res; 2000 May; 60(10):2584-8. PubMed ID: 10825125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
    Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of galectin-1 and galectin-3 in renal cell carcinoma; immunohistochemical study.
    Aboulhagag NA; El-Deek HEM; Sherif MF
    Ann Diagn Pathol; 2018 Oct; 36():31-37. PubMed ID: 30055522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas.
    Delorge S; Saussez S; Pelc P; Devroede B; Marchant H; Burchert M; Zeng FY; Danguy A; Salmon I; Gabius HJ; Kiss R; Hassid S
    Otolaryngol Head Neck Surg; 2000 Jun; 122(6):834-41. PubMed ID: 10828795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous lectins (galectins-1 and -3) as probes to detect differentiation-dependent alterations in human squamous cell carcinomas of the oropharynx and larynx.
    Plzak J; Smetana K; Betka J; Kodet R; Kaltner H; Gabius HJ
    Int J Mol Med; 2000 Apr; 5(4):369-72. PubMed ID: 10719052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression.
    Sanjuán X; Fernández PL; Castells A; Castronovo V; van den Brule F; Liu FT; Cardesa A; Campo E
    Gastroenterology; 1997 Dec; 113(6):1906-15. PubMed ID: 9394730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sertoli cell expression of galectin-1 and -3 and accessible binding sites in normal human testis and Sertoli cell only-syndrome.
    Wollina U; Schreiber G; Görnig M; Feldrappe S; Burchert M; Gabius HJ
    Histol Histopathol; 1999 Jul; 14(3):779-84. PubMed ID: 10425546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival.
    Merseburger AS; Kramer MW; Hennenlotter J; Serth J; Kruck S; Gracia A; Stenzl A; Kuczyk MA
    World J Urol; 2008 Dec; 26(6):637-42. PubMed ID: 18594826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation.
    Tinari N; Kuwabara I; Huflejt ME; Shen PF; Iacobelli S; Liu FT
    Int J Cancer; 2001 Jan; 91(2):167-72. PubMed ID: 11146440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis.
    Gordower L; Decaestecker C; Kacem Y; Lemmers A; Gusman J; Burchert M; Danguy A; Gabius H; Salmon I; Kiss R; Camby I
    Neuropathol Appl Neurobiol; 1999 Aug; 25(4):319-30. PubMed ID: 10476049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells.
    Ohannesian DW; Lotan D; Thomas P; Jessup JM; Fukuda M; Gabius HJ; Lotan R
    Cancer Res; 1995 May; 55(10):2191-9. PubMed ID: 7743523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma.
    Shimazui T; Kojima T; Onozawa M; Suzuki M; Asano T; Akaza H
    Oncol Rep; 2006 May; 15(5):1181-4. PubMed ID: 16596183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.